Certified by Founder Lodge
Illimis Therapeutics
Korea, Republic Of - Seoul
START UP
1 Disclosed Funding Rounds $42,000,000
0 Participating Investments
-
Founded date
2021
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiate
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 15 ,2025 | Series B | $42,000,000 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Auriga Space | $6,000,000 | (Jul 16, 2025)
Dextall | $15,000,000 | (Jul 15, 2025)
Circuit(US) | $4,500,000 | (Jul 15, 2025)
Duranta | $7,000,000 | (Jul 15, 2025)
RealSense | $50,000,000 | (Jul 15, 2025)
